NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Akebia Therapeutics, Inc. (AKBA) Stock Analysis

Akebia Therapeutics, Inc. (AKBA) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

AKBA

$0.98

−$0.01 (−0.81%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AKBA with… →

AKBA Key Statistics

As of Sep 4, 2026
Trading
Open
$0.99
Previous Close
$0.98
Day's Range
0.95–1.00
52-Week Range
0.81–3.20
Volume
8.35M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.19
Valuation
Market Cap
$270.10M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.23
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.12
Financials (FY)
Revenue (FY)
$236.20M+47.46%
Net Income (FY)
−$5.35M
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.54%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
277.11M
1-Year Return
−67.72%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
6.21M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AKBA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.44%
2025−15.26%
2024+53.23%
2023+114.90%
2022−74.47%
2021−19.29%
2020−55.70%
2019+14.29%
2018−62.81%
2017+42.84%
2016 (partial year)+19.24%

As of September 4, 2026.

AKBA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$236.20M−$5.35M−2.3%
2024$160.18M−$69.41M−43.3%
2023$194.62M−$51.93M−26.7%
2022$292.48M−$94.23M−32.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$236.20M$196.73M$23.50M−$5.35M−2.3%
2024$160.18M$97.00M−$50.41M−$69.41M−43.3%
2023$194.62M$120.47M−$46.08M−$51.93M−26.7%
2022$292.48M$206.92M−$64.85M−$94.23M−32.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AKBA Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricAKBADrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.232.3046% below
Profit margin−13.54%−3.14%10.4 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Akebia Therapeutics, Inc. (AKBA) is capitalised at $270.10M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 194 employees.

Over the past 52 weeks the price has ranged from $0.81 to $3.20. The most recent close on file for AKBA is $0.98, dated September 4, 2026. That is −$0.01 (−0.81%) against the previous close. The latest close sits 19.78% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $236.20M. Against the prior fiscal year total of $160.18M, that is a change of +47.46%. The same year closed with a net loss of $5.35M. Profit margin runs at −13.54%. That is 10.4 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.12.

Across the 4 fiscal years on file, revenue moves from $292.48M in 2022 to $236.20M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1.23. On price-to-sales that is 46.31% below the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −67.72%. Measured over 10 years, that is −19.21% a year compounded. Beta against the wider market is reported at 0.19. Annualized volatility over the trailing 10 years is 85.31%.

Growth & Income

The record shows no dividend for AKBA.

So far in 2026 the price is −39.44%. The strongest complete calendar year on file is 2023 at +114.90%; the weakest is 2022 at −74.47%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Akebia Therapeutics, Inc. (AKBA) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Akebia Therapeutics, Inc. AKBA $270.10M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Akebia Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Visit website →